Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher
Moneycontrol • 1 day ago
Key Investment Pillars
- Competition in key products: Increasing competition in gTolvaptan and gMirabegron is expected to negatively impact Lupin's revenue and profitability.
- Niche pipeline opportunities: Lupin has a strong pipeline of niche products, including 505(b)(2) opportunities and biosimilars, which are expected to drive growth.
- US market strategy: The company's strategy to expand complex products, including respiratory, injectables, and biosimilars, is expected to drive growth in the US market.
- India formulation growth: Lupin's India formulation business is expected to continue growing, driven by a strong product portfolio and increasing market share.
Thesis Validation Checklist
To validate the analyst's thesis, investors should watch for the following signals over the next 12 months:
- Competition intensity in key products: Any increase in competition in gTolvaptan and gMirabegron could negatively impact Lupin's revenue and profitability.
- Progress on niche pipeline opportunities: Successful launches of niche products, such as 505(b)(2) opportunities and biosimilars, could drive growth and improve profitability.
- US market performance: The company's ability to execute its US market strategy and expand complex products will be crucial to driving growth.
- India formulation growth: Continued growth in Lupin's India formulation business will be important to offset declining revenue from key products.